Published in Cell on April 02, 2010
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Controlling escape from angiogenesis inhibitors. Nat Rev Cancer (2012) 1.81
VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci U S A (2011) 1.67
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer (2011) 1.48
The discovery of placenta growth factor and its biological activity. Exp Mol Med (2012) 1.43
PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med (2012) 1.32
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A (2011) 1.26
r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction. PLoS One (2010) 1.13
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer (2011) 1.07
Overcoming resistance to antiangiogenic therapies. Oncologist (2012) 1.05
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb Perspect Biol (2013) 1.01
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci U S A (2012) 0.98
Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther (2013) 0.96
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A (2013) 0.95
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene (2011) 0.92
The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer (2013) 0.91
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res (2016) 0.91
Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer. Genes Cancer (2010) 0.90
Myeloid cells and lymphangiogenesis. Cold Spring Harb Perspect Med (2012) 0.88
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res (2013) 0.88
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget (2014) 0.87
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Role of placenta growth factor in cancer and inflammation. Exp Mol Med (2012) 0.86
FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J Exp Med (2015) 0.86
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett (2014) 0.86
PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors. Sci Adv (2015) 0.84
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med (2015) 0.84
Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis. Oncotarget (2016) 0.82
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci (2014) 0.82
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma. PLoS One (2015) 0.81
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain. Cancer Cell (2015) 0.80
Placenta growth factor expression is regulated by hydrogen peroxide in vascular smooth muscle cells. Am J Physiol Cell Physiol (2010) 0.80
Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts. Int J Mol Sci (2013) 0.79
β-hairpin peptide that targets vascular endothelial growth factor (VEGF) receptors: design, NMR characterization, and biological activity. J Biol Chem (2011) 0.79
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci (2013) 0.79
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro Oncol (2016) 0.79
The discovery of angiogenic growth factors: the contribution of Italian scientists. Vasc Cell (2014) 0.77
Placental growth factor inhibition for choroidal neovascularization. J Ophthalmic Vis Res (2013) 0.76
PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms. Int J Mol Sci (2016) 0.75
Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. BMC Cancer (2016) 0.75
PlGF, immune system and hypertension. Oncotarget (2015) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 5.15
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 4.93
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology (2004) 4.25
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell (2005) 3.75
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) (2005) 2.89
Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 2.83
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol (2003) 2.71
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Role of VEGF-A in vascularization of pancreatic islets. Curr Biol (2003) 2.56
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development (2007) 2.45
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A (2005) 2.38
Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol (2008) 2.35
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med (2009) 2.29
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature (2013) 1.98
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93